Tiragolumab
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma[1][2][3][4].
Product Specifications
CAS Number
1918185-84-8
Product Name Alternative
MTIG-7192A; RG-6058
UNSPSC
12352203
Target
CD28
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tiragolumab.html
Purity
99.04
Solubility
H2O
Smiles
[Tiragolumab]
Molecular Weight
(148.66 kDa)
References & Citations
[1]Houssaini MS, et al. Advances in the management of non-small cell lung cancer (NSCLC) : A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239. |[2]Caruso C. Tiragolumab Impresses in Multiple Trials. Cancer Discov. 2020 Aug;10 (8) :1086-1087. |[3]Shen X, et al. TIGIT-Fc Promotes Antitumor Immunity. Cancer Immunol Res. 2021 Sep;9 (9) :1088-1097. |[4]Dai T, et al. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Sci Rep. 2024 May 9;14 (1) :10661.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
